DelistingJun 26, 2026, 05:36 PM
Outlook Therapeutics Regains Nasdaq Minimum Bid Price Compliance
AI Summary
Outlook Therapeutics, Inc. announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company had previously received a delisting notice on February 18, 2026, for failing to maintain a $1.00 bid price. On June 26, 2026, Nasdaq confirmed that the company's common stock had traded at or above $1.00 for ten consecutive business days, thereby resolving the compliance issue.
Key Highlights
- Outlook Therapeutics received a delisting notice on February 18, 2026, for failing to maintain a $1.00 minimum bid price.
- The company regained compliance with Nasdaq Listing Rule 5550(a)(2) on June 26, 2026.
- Common stock maintained a closing bid price of $1.00 or greater for 10 consecutive business days.
- The compliance period was between June 11, 2026, and June 25, 2026.
- Nasdaq has confirmed that this delisting matter is now closed.
Price Impact
More from OTLK
USFDAJun 16, 8:03 AM
Outlook Therapeutics FDA Accepts BLA Resubmission; PDUFA July 29, 2026
AGM/EGMJun 1, 5:00 PM
Outlook Therapeutics Special Meeting on July 16 to Vote on Warrant Issuance, Share Increase, and Reverse Split
USFDAJun 1, 8:47 AM
Outlook Therapeutics Resubmits BLA for ONS-5010/LYTENAVA to FDA